NCT03144713View on ClinicalTrials.gov

Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 28, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Cirrhosis
Interventions
DRUG

Terlipressin

Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)

DRUG

Midodrine

Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)

DRUG

Albumin

Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.

Trial Locations (1)

110070

Institute of Liver and Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT03144713 - Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis | Biotech Hunter | Biotech Hunter